Konverge

Olmesartan medoxomil and amlodipine, the active ingredients in Konverge, are an angiotensin II receptor blocker and a calcium channel blocker presented as a tablet for oral use. They are used to treat hypertension in adult patients. GNH USA supplies Konverge as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Konverge, a combination of an ARB and a calcium‑channel blocker, is indicated for the management of high blood pressure.

Hypertension: lowers systolic and diastolic blood pressure and helps reduce the risk of cardiovascular complications. Essential hypertension: provides sustained blood pressure control when monotherapy is insufficient. Secondary hypertension: may be added to other agents to achieve target blood pressure in resistant cases.

Konverge may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Peripheral edema, especially of the ankles - Flushing or warmth sensation - Fatigue or tiredness - Palpitations or irregular heartbeat

Serious or Rare Side Effects: - Angioedema, including swelling of the face, lips, tongue, or throat - Severe hypotension leading to fainting - Hepatic dysfunction or elevated liver enzymes - Acute kidney injury or worsening renal function - Myocardial infarction or chest pain in susceptible patients - Allergic skin reactions such as rash or urticaria

Before initiating Konverge, clinicians should assess patient‑specific factors and monitor for potential risks.

Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. Renal function assessment: evaluate creatinine and electrolytes, especially in patients with pre‑existing kidney disease. Hepatic impairment: use with caution in moderate to severe liver disease. Elderly patients: start at lower doses and monitor for orthostatic symptoms. Pregnancy: avoid use as safety in pregnancy has not been established. Store at room temperature: keep below 25 °C, in the original container, protected from moisture and light.

Konverge can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren (in patients with diabetes or renal impairment): risk of severe hypotension and renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause hyperkalaemia when combined with olmesartan. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine plasma levels, raising the risk of edema and hypotension. - NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., beta‑blockers, ACE inhibitors): may enhance blood‑pressure lowering, requiring dose adjustments. - Grapefruit juice: modestly increases amlodipine exposure. - Lithium: concurrent use may raise lithium concentrations, necessitating serum level monitoring. - Diuretics: may potentiate electrolyte disturbances, especially potassium loss.